Progress in retinal and eye research · 2024
Value proposition of retinal imaging in Alzheimer's disease screening: A review of eight evolving trends.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chan Victor T T, Ran An Ran, Wagner Siegfried K, Hui Herbert Y H, Hu Xiaoyan, Ko Ho, Fekrat Sharon, Wang Yaxing, Lee Cecilia S, Young Alvin L, Tham Clement C, Tham Yih Chung, Keane Pearse A, Milea Dan, Chen Christopher, Wong Tien Yin, Mok Vincent C T, Cheung Carol Y
Аннотация
Alzheimer's disease (AD) is the leading cause of dementia worldwide. Current diagnostic modalities of AD generally focus on detecting the presence of amyloid β and tau protein in the brain (for example, positron emission tomography [PET] and cerebrospinal fluid testing), but these are limited by their high cost, invasiveness, and lack of expertise. Retinal imaging exhibits potential in AD screening and risk stratification, as the retina provides a platform for the optical visualization of the central nervous system in vivo, with vascular and neuronal changes that mirror brain pathology. Given the paradigm shift brought by advances in artificial intelligence and the emergence of disease-modifying therapies, this article aims to summarize and review the current literature to highlight 8 trends in an evolving landscape regarding the role and potential value of retinal imaging in AD screening.